LENZ Therapeutics (LENZ) Stock Analysis & Winston Score

LENZ Therapeutics is a small biotech company focused on eye care medicines. Its lead product is LNZ100, a eye drop designed to treat presbyopia, which is the age-related condition that makes it hard for people to read small text up close. The company targets adults over 40, a very large and growing patient population, and sells through eye care professionals.

LENZ makes money by developing and eventually selling prescription eye drops, though as of now it is still in the clinical and early commercial stage and is not yet profitable — reflected in its deeply negative operating margin. The company operates primarily in the United States and is very small, with a market cap around $200 million. Its main competitive challenge is breaking into a market where larger, established eye care companies already have similar products, including Allergan's Vuity. The key risk is whether LENZ can gain enough commercial traction and physician adoption to build a sustainable business before it runs out of cash.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-149.1% YoY

YoY Growth Rate

Earnings declining

Insider Activity

12.7%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 months

$25M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

LENZ Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

37.6%

Modest — 37.6% gross margin

Operating Margin

-2321.7%

Losing money on operations — -2321.7%

ROCE

-17.9%

Weak — -17.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-416.6%

Burning cash (-416.6%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial